Aquestive Therapeutics, Inc. announced that Lori J. Braender will step down from her roles as Chief Legal Officer and Chief Compliance Officer effective April 2, 2026, while remaining as Corporate Secretary through at least year-end. Thomas A. Zalewski was appointed as the new Chief Legal Officer and Chief Compliance Officer effective the same date.
Key takeaways
Lori J. Braender steps down as Chief Legal Officer and Chief Compliance Officer effective 2026-04-02; remains Corporate Secretary.
Thomas A. Zalewski, former Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective 2026-04-02.
Braender entitled to pro rata 2026 target bonus, 12 months of severance payments after 2026-05-07, COBRA coverage for 12 months, and full vesting of unvested equity on 2026-05-07.
Zalewski receives inducement grant of 100,000 RSUs and 75,000 stock options, vesting 25% after years 1-2 and 50% after year 3.